MX2023006719A - Degradadores de cinasas asociadas con el receptor de interleucina 1 (irak) y sus usos. - Google Patents
Degradadores de cinasas asociadas con el receptor de interleucina 1 (irak) y sus usos.Info
- Publication number
- MX2023006719A MX2023006719A MX2023006719A MX2023006719A MX2023006719A MX 2023006719 A MX2023006719 A MX 2023006719A MX 2023006719 A MX2023006719 A MX 2023006719A MX 2023006719 A MX2023006719 A MX 2023006719A MX 2023006719 A MX2023006719 A MX 2023006719A
- Authority
- MX
- Mexico
- Prior art keywords
- degraders
- irak
- interleukin
- receptor
- kinases associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Liquid Crystal Substances (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063123330P | 2020-12-09 | 2020-12-09 | |
| PCT/US2021/062640 WO2022125790A1 (en) | 2020-12-09 | 2021-12-09 | Irak degraders and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006719A true MX2023006719A (es) | 2023-06-23 |
Family
ID=81973811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006719A MX2023006719A (es) | 2020-12-09 | 2021-12-09 | Degradadores de cinasas asociadas con el receptor de interleucina 1 (irak) y sus usos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230096599A1 (enExample) |
| EP (1) | EP4259128A4 (enExample) |
| JP (1) | JP7832945B2 (enExample) |
| KR (1) | KR20230130179A (enExample) |
| CN (1) | CN116669722A (enExample) |
| AR (1) | AR124294A1 (enExample) |
| AU (1) | AU2021396308A1 (enExample) |
| CA (1) | CA3200608A1 (enExample) |
| CO (1) | CO2023006818A2 (enExample) |
| IL (1) | IL303458A (enExample) |
| MX (1) | MX2023006719A (enExample) |
| TW (1) | TW202237601A (enExample) |
| WO (1) | WO2022125790A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| CN116867758A (zh) * | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| WO2024020084A1 (en) * | 2022-07-20 | 2024-01-25 | Bristol-Myers Squibb Company | Heteroaryl compounds as ligand directed degraders of irak4 |
| IL325910A (en) * | 2023-07-13 | 2026-03-01 | Increland | Aromatic compound, pharmaceutical preparation comprising the same, and use thereof |
| CN121816348A (zh) | 2023-08-11 | 2026-04-07 | 深圳众格生物科技有限公司 | 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用 |
| WO2025051160A1 (zh) * | 2023-09-08 | 2025-03-13 | 北京华益健康药物研究中心 | 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途 |
| CN120025333A (zh) * | 2023-11-22 | 2025-05-23 | 广东东阳光药业股份有限公司 | 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途 |
| WO2025168131A1 (zh) * | 2024-02-08 | 2025-08-14 | 清华大学 | 一种多靶降解剂及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6126131B2 (ja) * | 2012-01-10 | 2017-05-10 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| CA2988461A1 (en) * | 2015-06-26 | 2016-12-29 | Dana-Farber Cancer Institute, Inc. | Fused bicyclic pyrimidine derivatives and uses thereof |
| WO2017007612A1 (en) * | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3445765A4 (en) * | 2016-04-22 | 2019-09-18 | Dana Farber Cancer Institute, Inc. | DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE |
| EP3710443A1 (en) * | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2020010227A1 (en) * | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CA3119773A1 (en) * | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021053555A1 (en) * | 2019-09-16 | 2021-03-25 | Novartis Ag | Glue degraders and methods of use thereof |
| KR20230005160A (ko) * | 2020-03-19 | 2023-01-09 | 카이메라 쎄라퓨틱스 인코포레이티드 | Mdm2 분해제 및 이의 용도 |
-
2021
- 2021-12-09 IL IL303458A patent/IL303458A/en unknown
- 2021-12-09 AU AU2021396308A patent/AU2021396308A1/en not_active Abandoned
- 2021-12-09 KR KR1020237023081A patent/KR20230130179A/ko active Pending
- 2021-12-09 CN CN202180090865.XA patent/CN116669722A/zh active Pending
- 2021-12-09 EP EP21904406.2A patent/EP4259128A4/en active Pending
- 2021-12-09 US US17/643,560 patent/US20230096599A1/en not_active Abandoned
- 2021-12-09 JP JP2023534948A patent/JP7832945B2/ja active Active
- 2021-12-09 CA CA3200608A patent/CA3200608A1/en active Pending
- 2021-12-09 WO PCT/US2021/062640 patent/WO2022125790A1/en not_active Ceased
- 2021-12-09 AR ARP210103419A patent/AR124294A1/es unknown
- 2021-12-09 TW TW110146161A patent/TW202237601A/zh unknown
- 2021-12-09 MX MX2023006719A patent/MX2023006719A/es unknown
-
2023
- 2023-05-25 CO CONC2023/0006818A patent/CO2023006818A2/es unknown
-
2025
- 2025-02-18 US US19/056,013 patent/US20250375526A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4259128A4 (en) | 2025-04-30 |
| AR124294A1 (es) | 2023-03-15 |
| US20250375526A1 (en) | 2025-12-11 |
| CO2023006818A2 (es) | 2023-07-10 |
| AU2021396308A1 (en) | 2023-06-22 |
| TW202237601A (zh) | 2022-10-01 |
| CN116669722A (zh) | 2023-08-29 |
| IL303458A (en) | 2023-08-01 |
| JP7832945B2 (ja) | 2026-03-18 |
| JP2023552827A (ja) | 2023-12-19 |
| EP4259128A1 (en) | 2023-10-18 |
| WO2022125790A1 (en) | 2022-06-16 |
| US20230096599A1 (en) | 2023-03-30 |
| CA3200608A1 (en) | 2022-06-16 |
| KR20230130179A (ko) | 2023-09-11 |
| AU2021396308A9 (en) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023006719A (es) | Degradadores de cinasas asociadas con el receptor de interleucina 1 (irak) y sus usos. | |
| MX2023007852A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| MX2024009390A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos | |
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| CO2022008406A2 (es) | Degradadores de irak y usos de los mismos | |
| MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| MX2022002877A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. | |
| CO2021007068A2 (es) | Degradadores de irak y usos de los mismos | |
| CO2021013339A2 (es) | Degradadores de stat y usos de los mismos | |
| CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
| WO2021127283A3 (en) | Irak degraders and uses thereof | |
| CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
| CO2022001210A2 (es) | Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes | |
| MX2021009259A (es) | Conjugados de il-2 y metodos de uso del mismo. | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| CO2020010303A2 (es) | Conjugados de il-15, y sus usos | |
| MX2020006812A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| MX2022011437A (es) | Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos. | |
| MX2021005171A (es) | Inhibidores de cinasas reguladas por señal extracelular (erk) y usos de los mismos. | |
| MX2024008964A (es) | Analogos de rapamicina y usos de los mismos. | |
| CO2022012594A2 (es) | Inhibidores del eif4e y sus usos | |
| CO2025009897A2 (es) | Degradadores de irak y usos de los mismos | |
| CO2021000147A2 (es) | Composición agrícola | |
| MX2023008634A (es) | Análogos de rapamicina y usos de estos. | |
| MX2025012761A (es) | Moleculas y metodos de uso de estas |